

# بسم الله الرحمن الرحيم



HOSSAM MAGHRABY



# شبكة المعلومات الجامعية التوثيق الالكتروني والميكروفيلم



HOSSAM MAGHRABY



# جامعة عين شمس

## التوثيق الإلكتروني والميكروفيلم

### قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها  
على هذه الأقراص المدمجة قد أعدت دون أية تغيرات



## يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار



HOSSAM MAGHRABY



# **Unconjugated Bilirubin in Patients with Schizophrenia in Acute episode**

Thesis

*Submitted for Partial Fullfilment of Master Degree in  
Neurpsychiatry*

Submitted by

***Maha Sabry Mohamed Abdellatif Omar***

*M.B.B.CH, Faculty of Medicine - Ain Shams University*

Under supervision of

**Prof. Afaf Mohamed Abd-Elsamei**

*Professor of Psychiatry*

*Faculty of Medicine - Ain Shams University*

**Dr. Dina Mohamed El Gabry**

*Assistant Professor of Psychiatry*

*Faculty of Medicine - Ain Shams University*

**Dr. Rehab Serag Mohammad**

*Lecturer of Psychiatry*

*Faculty of Medicine - Ain Shams University*

Faculty of Medicine  
Ain Shames University

2021

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

لسبحانك لا علم لنا  
إلا ما علمتنا إنك أنت  
العليم العظيم

صدق الله العظيم

سورة البقرة الآية: ٢٢

# Acknowledgment

*First and foremost, I feel always indebted to **ALLAH**, the Most Kind and Most Merciful.*

*I'd like to express my respectful thanks and profound gratitude to **Prof. Afaf Mohamed Abd-Elsamei**, Professor of Psychiatry - Faculty of Medicine- Ain Shams University for her keen guidance, kind supervision, valuable advice and continuous encouragement, which made possible the completion of this work.*

*I am also delighted to express my deepest gratitude and thanks to **Dr. Dina Mohamed El Gabry**, Assistant Professor of Psychiatry, Faculty of Medicine, Ain Shams University, for her kind care, continuous supervision, valuable instructions, constant help and great assistance throughout this work.*

*I am deeply thankful to **Dr. Rehab Serag Mohammad**, Lecturer of Psychiatry, Faculty of Medicine, Ain Shams University, for her great help, active participation and guidance.*

*I would like to express my hearty thanks to all my family, friends and colleagues for their support till this work was completed.*

*Last but not least my sincere thanks and appreciation to all patients participated in this study.*

***Maha Sabry Mohamed Abdellatif Omar***

# *List of Contents*

Title	Page No.
<b>List of Tables .....</b>	<b>i</b>
<b>List of Figures .....</b>	<b>iii</b>
<b>List of Abbreviations.....</b>	<b>iv</b>
<b>Introduction.....</b>	<b>1</b>
<b>Aim of the Work.....</b>	<b>4</b>
<b>Review of Literature</b>	
Chapter (1): Schizophrenia.....	5
Chapter (2): Peripheral Blood Changes in Schizophrenia .....	25
Chapter (3): Unconjugated Bilirubin and its Relationship to Schizophrenia .....	39
<b>Subjects and Methods.....</b>	<b>57</b>
<b>Results .....</b>	<b>70</b>
<b>Discussion .....</b>	<b>83</b>
<b>Strengths .....</b>	<b>98</b>
<b>Limitations .....</b>	<b>98</b>
<b>Conclusion .....</b>	<b>99</b>
<b>Recommendations.....</b>	<b>99</b>
<b>Summary .....</b>	<b>101</b>
<b>References .....</b>	<b>107</b>
<b>Arabic Summary.....</b>	<b>١</b>

## *List of Tables*

Table No.	Title	Page No.
<b>Table (1):</b>	Sociodemographic data of the sample: .....	71
<b>Table (2):</b>	Anthropometric measures of the sample: .....	72
<b>Table (3):</b>	Post Hoc analysis of anthropometric measures: .....	72
<b>Table (4):</b>	Clinical data of relapse and remission groups:.....	73
<b>Table (5):</b>	Total, conjugated and unconjugated bilirubin mean serum levels ( <i>mg/dL</i> ) in relapse and remission: .....	74
<b>Table (6):</b>	Post Hoc analysis of total and conjugated bilirubin mean serum levels: .....	75
<b>Table (7):</b>	Relation of total bilirubin mean serum levels ( <i>mg/dL</i> ) to gender, smoking, family psychiatric history, and antipsychotic use in relapse and remission groups:.....	76
<b>Table (8):</b>	Relation of indirect bilirubin mean serum levels ( <i>mg/dL</i> ) to gender, smoking, family psychiatric history, and antipsychotic use in relapse and remission groups:.....	76
<b>Table (9):</b>	Relation of direct bilirubin mean serum levels ( <i>mg/dL</i> ) to gender, smoking, family psychiatric history, and antipsychotic use in and remission groups: .....	77
<b>Table (10):</b>	Relation of total, direct, and indirect bilirubin mean serum levels ( <i>mg/dL</i> ) to gender and smoking in the healthy group: .....	77
<b>Table (11):</b>	Correlation of bilirubin serum levels with age and anthropometric in the studied groups:.....	78



## *List of Tables (Cont...)*

Table No.	Title	Page No.
<b>Table (12):</b>	Correlation of bilirubin serum levels with duration of psychotic disorder and with duration of untreated psychosis in both relapse and remission groups:.....	79
<b>Table (13):</b>	Correlation of bilirubin serum levels with psychopathology in the relapse group: .....	80
<b>Table (14):</b>	Correlation of bilirubin serum levels with psychopathology in the remission group:.....	82
<b>Table (15):</b>	Correlation of bilirubin mean serum levels with psychosocial & cognitive functioning in relapse and remission group using GAF & TMT-A & TMT-B:.....	82

# *List of Figures*

Fig. No.	Title	Page No.
<b>Figure (1):</b>	A schematic representation of central nervous system-peripheral blood tissue interactions .....	27
<b>Figure (2):</b>	Representation of potential peripheral biomarkers for schizophrenia .....	38
<b>Figure (3):</b>	A Schematic representation of bilirubin metabolism. ....	41
<b>Figure (4):</b>	Schematic overview of the proposed pathophysiological mechanisms underlying bilirubin-induced neuronal injury.....	49
<b>Figure (5):</b>	Schematic of factors contributing to bilirubin-albumin hemodynamic.....	53
<b>Figure (6):</b>	The correlation between total bilirubin serum levels and total PANSS score in the relapse group. ....	80
<b>Figure (7):</b>	The correlation between indirect bilirubin serum levels and total PANSS score in the relapse group. ....	80
<b>Figure (8):</b>	The correlation between total bilirubin serum levels and general psychopathology total score (GTS) in the relapse group. ....	81
<b>Figure (9):</b>	The correlation between indirect bilirubin serum levels and general psychopathology total score (GTS) in the relapse group. ....	81

# *List of Abbreviations*

<b>Abb.</b>	<b>Full term</b>
<i>5-HT</i> .....	<i>5-hydroxytryptamine</i>
<i>6-GP</i> .....	<i>P-glycoprotein</i>
<i>ABOi</i> .....	<i>ABO incompatibility</i>
<i>AChR</i> .....	<i>Alpha 7 acetylcholine receptor</i>
<i>AMPA</i> .....	<i><math>\alpha</math>-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor</i>
<i>B+A complex</i> .....	<i>Bilirubin albumin complex</i>
<i>BBB</i> .....	<i>Blood–brain barrier</i>
<i>BE</i> .....	<i>Bilirubin encephalopathy</i>
<i>BMI</i> .....	<i>Body mass index</i>
<i>BPRS</i> .....	<i>Brief Psychiatric Rating Scale</i>
<i>CB2</i> .....	<i>Cannabinoid receptor 2</i>
<i>CBC</i> .....	<i>Complete blood count</i>
<i>CDSS</i> .....	<i>Calgary Depression Scale for Schizophrenia</i>
<i>CGI-SCH</i> .....	<i>Clinical Global Impression-Schizophrenia</i>
<i>CNS</i> .....	<i>Central nervous system</i>
<i>CO</i> .....	<i>Carbon monoxide</i>
<i>CSF</i> .....	<i>Cerebrospinal fluid</i>
<i>D</i> .....	<i>Diagnostic</i>
<i>DA</i> .....	<i>Dopamine</i>
<i>DARPP-32</i> .....	<i>DA- and cAMP-regulated neuronal phosphoprotein of 32 kDa</i>
<i>DEF<math>\alpha</math>4</i> .....	<i>Defensin <math>\alpha</math>4</i>
<i>EAAT</i> .....	<i>Excitatory amino acid transporter;</i>
<i>ECT</i> .....	<i>Electro-convulsive therapy</i>
<i>EEG</i> .....	<i>Electroencephalogram</i>
<i>G6PD def</i> .....	<i>Glucose-6- phosphate dehydrogenase deficiency</i>
<i>GABA</i> .....	<i><math>\gamma</math>-aminobutyric acid</i>
<i>GAD</i> .....	<i>Glutamic acid decarboxylase</i>

## *List of Abbreviations (cont...)*

<b>Abb.</b>	<b>Full term</b>
<i>GAF</i> .....	<i>Global Assessment of Functioning</i>
<i>GSK3<math>\alpha</math></i> .....	<i>Glycogen synthase kinase 3<math>\alpha</math></i>
<i>HVA</i> .....	<i>Homovanillic acid</i>
<i>IFN-<math>\gamma</math></i> .....	<i>Interferon-<math>\gamma</math></i>
<i>IL</i> .....	<i>Interleukins</i>
<i>IL-1<math>\beta</math></i> .....	<i>Interleukin-1<math>\beta</math></i>
<i>IL-2</i> .....	<i>Interleukin-2</i>
<i>IL2R<math>\alpha</math></i> .....	<i>Interleukin-2 receptor-<math>\alpha</math></i>
<i>IL-6</i> .....	<i>Interleukin-6</i>
<i>IL-8</i> .....	<i>Interleukin-8</i>
<i>KainateR</i> .....	<i>Kainate receptor</i>
<i>mC</i> .....	<i>Methylated deoxycytidine</i>
<i>MRP-1</i> .....	<i>Multidrug resistant protein-1</i>
<i>NADP<math>^{+}</math></i> .....	<i>Nicotinamide adenine dinucleotide phosphate;</i>
<i>NADPH</i> .....	<i>Reduced form of NADP<math>^{+}</math></i>
<i>NE</i> .....	<i>Norepinephrine</i>
<i>NMDA</i> .....	<i>Glutamate and N-methyl-D-aspartate</i>
<i>NMDA</i> .....	<i>N-methyl-D-aspartate</i>
<i>NMDAR</i> .....	<i>N-methyl-D-aspartate receptor;</i>
<i>NS</i> .....	<i>Nonspecific</i>
<i>PANSS</i> .....	<i>Positive and Negative Syndrome Scale</i>
<i>PBMC</i> .....	<i>Peripheral blood mononuclear cells</i>
<i>RBCs</i> .....	<i>Red blood cells;</i>
<i>Rhi</i> .....	<i>Rh Rhesus blood group incompatibility</i>
<i>S100A12</i> .....	<i>S100 calcium binding protein A12</i>
<i>SANS</i> .....	<i>Scale for the Assessment of Negative Symptoms</i>
<i>SAPS</i> .....	<i>Scale for the Assessment of Positive Symptoms</i>



## *List of Abbreviations (cont...)*

Abb.	Full term
<i>SCID-I</i> .....	<i>Structured Clinical Interview for DSM-IV™ Axis I Disorders</i>
<i>SELENBP1</i> .....	<i>Selenium-binding protein 1</i>
<i>TH</i> .....	<i>Tyrosine hydroxylase</i>
<i>TMT</i> .....	<i>Trail Making Test</i>
<i>TNF</i> .....	<i>Tumor necrosis factor</i>
<i>TR</i> .....	<i>Treatment response</i>
<i>UDP</i> .....	<i>Uridine diphosphate</i>
<i>UGT1A1</i> .....	<i>Uridine diphosphate-glucuronyl transferase 1A1</i>
<i>VCAM-1</i> .....	<i>Vascular cell adhesion molecule 1</i>

# INTRODUCTION

Unconjugated bilirubin is the water insoluble fraction of total bilirubin in serum that crosses the blood brain barrier. Having antioxidant effects, it increases in response to the in situ neurotoxic psychotic episode (*Dore et al., 1999; Rund, 2014*). On the other hand, it has both direct and indirect toxic effects on central nervous system and brain tissue connectivity, even in healthy human subjects without bilirubin metabolism dysfunction, making neurons more susceptible to further inflammatory damage which is believed to underlie the clinical and cognitive symptoms of schizophrenia (*Glimore et al., 2004; Brites, 2012; Gama Marques et al., 2019*). Hence, it may be consequence or cause of a psychotic state.

Evidence supporting a correlation between unconjugated bilirubin and schizophrenia is considerable and most previous studies have managed to report a statistically relevant link between the two variables (*Dornelles et al., 2019*).

In animal studies, chronic microglial activation in Gunn rats by toxic levels of unconjugated bilirubin (due to genetic deficiency in glucuronyl transferase) has been found to contribute to behavioural and neuropsychological changes in these rats that might be attenuated by antipsychotics, as in human patients with schizophrenia (*Liaury et al., 2012; Tsuchie et al., 2013*). This rat has already been used as schizophrenia animal model (*Rice & Shapiro, 2008*).

In human studies, infants with neonatal unconjugated hyperbilirubinemia (due to decreased erythrocytes survival and deficient hepatic clearance) have presented with later diagnoses of mental disorders and shown a higher risk for schizophrenia when compared to a control group (*Jones, 1994; Dalman & Cullberg, 1999*).

Gilbert's syndrome (idiopathic chronic mild unconjugated hyperbilirubinemia due to genetic deficiency in UDP-glucuronosyltransferase-1 enzyme) is found in up to 10% of general population but reaches the double of that prevalence among patients with schizophrenia (*Bosma et al., 1995*).

Patients with schizophrenia especially during acute episode showed significantly higher frequency of elevated unconjugated bilirubin mean levels when compared with patients in remission phase, other psychiatric patients and general populations (*Muller et al., 1991; Bach et al. 2010*). They also showed a positive correlation between these higher levels and positive and negative syndrome scale (PANSS) score in addition to a poor outcome (*Powell & Hansen, 2007; Gama Marques and Arantes-Gonçalves, 2018*).

The interest of this literature lies in the possibility of finding an objective, measurable, and potentially influenceable parameter which could help complement the still somewhat subjective approach to the diagnosis, management, and even